Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
How to manage deviations in the most effective way
Eugenio Filippi is Senior Manager of the European Plasma Logistics and Dispositioning Center at BAXTER. He has already spoken at the Cold Chain online conference in August 2015.
Now Eugenio will present his case study "How to manage process deviations and showcase your data" at this Quality Assurance Pharma & Biotech online conference. As a short preview, we have asked Eugenio a few questions regarding his current topic:
Are pharma companies paying close enough attention to deviations?
Yes, for sure they are, the big question is whether they are doing so in the most effective way.
What are the basic steps in deviation management?
Most Quality Organizations are very focused on root cause analysis and defining corrective and preventive actions (CAPAs). I would argue that unless the data is gathered and analyzed correctly, this might not really bring the expected benefits. If your trending analysis never shows you any issues, are you looking at the right data?
How can we expect or predict particular deviations?
Generally speaking, wherever manual intervention is present in a process, you will sooner or later have human errors. Might not happen very often, but given equal opportunities for failure, it will happen. The fact that you have been lucky so far does not make your process robust forever.
What are the most common mistakes in deviation management?
Blaming your employees for their mistakes. You should be addressing the flawed process that has allowed them to make that mistake, and with their input, change it to eliminate those situations. A classic example is that you cannot start an automatic transmission car unless your foot is on the brake. This eliminates the situation of the user forgetting to engage the brake and possibly hitting a wall. Blaming them afterwards might be very costly.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.